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combination with gemcitabine and oxaliplatin until disease 
progression. Analyses of the EGFR pathway, including KRAS 
mutations, could be performed in 25 patients. Analyses were 
carried out following microdissection of the tumor.  Results: 
Fourteen (56%) of the 25 patients examined harbored a 
point mutation in codon 12 of the KRAS gene. No differences 
between the groups were noted in median progression-free 
survival (104 days in KRAS wild-type patients vs. 118 days in 
patients with KRAS mutations). Overall survival was longer in 
wild-type patients compared to patients with KRAS muta-
tions (263 vs. 162 days), but the difference did not reach sta-
tistical significance. A further analysis of our clinical phase II 
trial showed that the presence of a rash was significantly cor-
related with overall survival.  Conclusions: KRAS mutation 
in codon 12 may be associated with reduced survival com-
pared to KRAS wild type. The role of KRAS mutations for ce-
tuximab therapy in pancreatic cancer warrants further inves-
tigation in larger trials to exclude an epiphenomenon. Fur-
thermore, the development of a rash is indicative of clinical 
benefit.  Copyright © 2011 S. Karger AG, Basel 
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 Abstract 
 Background: Genetic alterations within the epidermal 
growth factor receptor (EGFR) pathway, including KRAS mu-
tations, have been demonstrated to be associated with re-
sponse to EGFR inhibitors like cetuximab in colorectal can-
cers. Mutations in the KRAS gene have been found in 70–
90% of pancreatic cancers. Unfortunately, the addition of 
cetuximab to chemotherapy did not increase response or 
survival in patients with advanced pancreatic cancer in 
phase II and phase III studies. The aim of this study was to 
evaluate the relationship between KRAS mutations and re-
sponse or survival in patients with metastatic pancreatic 
cancer treated with cetuximab plus chemotherapy.  Meth-
ods: Within a multicenter phase II trial, 64 patients with met-
astatic pancreatic cancer were treated with cetuximab in 
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 Introduction 
 The prognosis for patients with pancreatic adenocar-
cinoma is still dismal. Since 1997, gemcitabine has been 
accepted as the standard palliative chemotherapy for ad-
vanced pancreatic cancer, with a median survival of 6 
months  [1] . Many trials have been conducted evaluating 
various combination protocols. Meta-analysis of ran-
domized trials revealed that pancreatic cancer patients 
with good performance status appear to benefit from 
gemcitabine-based cytotoxic combinations  [2] . Never-
theless, data are conflicting as shown in a recently pub-
lished study by Colucci et al.  [3] . In this randomized 
phase III trial, the addition of weekly cisplatin to gem-
citabine failed to demonstrate any improvement as first-
line treatment of advanced pancreatic cancer.
 Therefore, there is a strong need for effective treatment 
modalities. With respect to molecular biology, the epider-
mal growth factor receptor (EGFR) has been shown to play 
an important role in carcinogenesis of pancreatic cancer 
 [4, 5] . Moore et al.  [6]  reported a statistically significant 
overall survival benefit of 0.33 months for erlotinib, an 
oral reversible inhibitor of EGFR tyrosine kinase, in com-
bination with gemcitabine compared with gemcitabine 
alone for first-line therapy in patients with advanced pan-
creatic cancer. Cetuximab, a monoclonal antibody target-
ing the EGFR, also resulted in promising activity in pre-
clinical and early clinical trials  [7, 8] . Thus, we recently 
conducted a phase II study to assess the ef ficacy and safe-
ty of cetuximab plus the combination of gemcitabine/ox-
aliplatin in metastatic pancreatic cancer  [9] . In 64 patients 
with metastatic pancreatic carcinoma the addition of ce-
tuximab to the combination of gemcitabine and oxalipla-
tin was well tolerated and exhibited a high response rate 
(33%). The median time to progression-free survival was 
3.9 months and overall survival was 7.1 months.
 The aim of this study was to evaluate the relationship 
between KRAS mutations and response or survival in 
patients with metastatic pancreatic cancer treated with 
cetuximab plus chemotherapy, based on tumor samples 
available from the recently conducted study  [9] .
 Methods 
 This study was conducted as part of a multicenter phase II 
trial of 64 patients with metastatic pancreatic cancer  [9] . Eligible 
patients were treated with cetuximab in combination with gem-
citabine and oxaliplatin until disease progression. All partici-
pants for mutation analysis gave written informed consent. Ethi-
cal approval for the retrospective use of paraffin material for the 
study was given by the ethical committee at the University of Re-
gensburg.
 Tumor material was available for the study from a total of 
25/64 (39%) patients, of whom 10 were from Regensburg, 4 from 
Augsburg, 4 from Halle, 4 from Frankfurt and 3 from Munich. 
For the remaining cases, there were either no paraffin blocks 
available or there was not sufficient tumor tissue in the block for 
molecular analysis. Analyses of KRAS mutations were performed 
at the Institute of Pathology in Erlangen. All pathologic speci-
mens were cut from formalin-fixed paraffin-embedded tumor 
blocks, and the HE-stained section was reviewed by one patholo-
gist (A.H.). Tumor cells were manually microdissected from par-
affin sections of 10-  m thickness under an inverted microscope 
to obtain a tumor cell population of 70%.
 DNA was isolated using the QIAamp  DNA FFPE Tissue Kit 
(QIAGEN, Hilden, Germany). Quantity and quality of the DNA 
were controlled using a spectral photometer (NanoDrop  , 
peQLab, Erlangen, Germany). Further details were described pre-
viously  [10] .
 Statistical analysis was performed using the SPlus software 
(Insightful Corp., Seattle, Wash., USA). Comparisons of Kaplan-
Meier curves were based on the two-sided log-rank test.
 Results 
 Baseline characteristics of the evaluable patient popu-
lation are shown in  table 1 . Fourteen (56%) of the 25 pan-
creatic adenocarcinomas examined harbored a point mu-
tation in the KRAS gene. All KRAS mutations occurred 
at codon 12. The distribution of different KRAS muta-
tions is shown in  figure 1 . The most frequently observed 
point mutation at codon 12 was GAT Gly12Asp followed 
by GTT Gly12 Val.
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 Fig. 1. Distribution of KRAS mutations. 
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 The presence of KRAS point mutations at codon 12 
adversely influenced median survival time [162 vs. 263 
days, KRAS mutation (+ vs. –),  fig. 2 ], but the difference 
did not reach statistical significance (p = 0.57; HR 1.33; 
95% CI 0.49–3.61). The overall survival rate after 6 months 
was 65% (95% CI 39–100%) in the wild-type group versus 
31% (95% CI 12–78%) in the group with KRAS codon 12 
mutations.
 Median progression-free survival was 104 days in the 
wild-type group compared to 118 days within the group 
with KRAS mutation (p = 0.63; HR 0.79). In the wild-
type group, progression-free survival after 6 months was 
20% (95% CI 6–69%) and 22% (95% CI 7–75%) in the 
group with KRAS codon 12 mutation. Correlation of the 
KRAS status with response is shown in   table 2 . A further 
analysis of our initial clinical phase II trial showed that 
the presence of a rash ( 6 grade 2) was significantly cor-
related with overall survival ( fig. 3 ). Sixty-one patients 
could be included in this analysis. Skin toxicity was usu-
ally mild to moderate (grade 1 or 2) in 43 (70%) patients; 
only 6 (10%) developed a grade 3 acne-like rash. Patients 
developing any grade of rash had a significantly longer 
median overall survival of 237 days compared to 148 
days for patients with no rash (p = 0.014; HR 2.37; 95% 
CI 1.16–4.85).
 Discussion 
 Systemic chemotherapy has so far failed to demon-
strate sufficient impact on the survival in patients with 
advanced pancreatic cancer. The EGFR pathway is a ra-
tional molecular target for an alternative therapeutic ap-
proach. After promising preclinical and clinical trials  [7, 
8] findings of further phase II and III studies suggest that 
Table 1. B aseline characteristics
Investigated 
subgroup 
of patients
Whole study 
population
Patients, n 25 62
Mean age (range), years 61.4 (37–72) 64.5 (31–78)
Male/female, n 19/6 41/21
Performance status, n
70 2 (10%) 6 (12%)
80 9 (43%) 13 (25%)
90–100 10 (28%) 33 (63%)
Distant metastasis, n
Lymph nodes (abdominal/pelvic) 1 (4%) 8 (1%)
Liver 23 (92%) 58 (93%)
Lung 4 (16%) 8 (1%)
Other 9 (36%) 22 (3%)
Adjuvant treatment (before start of trial), n 0 1
Time (days)
0
0 50 100 150 200 250 300 350 450 500 550
n = 11 10 7 5 4 3 1 1 0 0 0
n = 14 10 8 6 3 2 2 1 1 1 1
0.2
0.4
0.6
0.8
1.0
O
ve
ra
ll 
su
rv
iv
al
 ra
te
Wild type: n = 11, 7 events
Mutant: n = 14, 9 events
(Wild type)
(Mutant)
log-rank test: p = 0.57, two-sided
400
 Fig. 2. Overall survival depending on 
KRAS mutation. 
Table 2.  Correlation of KRAS status with response (%)
KRAS wild type
(n = 11)
KRAS mutation
(n = 13)
Total
(n = 24)
Complete response – – –
Partial response 2 (18) 5 (38) 7 (28)
Stable disease 4 (36) 1 (8) 5 (20)
Progressive disease 5 (45) 7 (54) 12 (50)
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cetuximab does not add any valuable activity to chemo-
therapy with gemcitabine or a combination of gemcitabi-
ne and cisplatin/oxaliplatin  [9, 11, 12] .
 Cascinu et al.  [11]  reported data of a phase II trial in 
which patients with advanced pancreatic cancer were ran-
domly assigned to treatment with cetuximab plus gem-
citabine and cisplatin or chemotherapy alone. Sixty-one of 
84 (73%) patients had metastatic disease. Seven of 40 
(17.5%) patients had an objective response rate in the ce-
tuximab group and 5/41 (12.2%) in the noncetuximab 
arm. No significant differences between the groups were 
noted in median progression-free survival or in median 
overall survival. Median progression-free survival was 3.4 
months in the cetuximab group and 4.2 months in the 
noncetuximab group. Median overall survival was 7.5 and 
7.8 months, respectively. Interestingly, toxic effects were 
not increased by cetuximab and at least 33/61 (54%) pa-
tients with metastastic disease received a second-line 
fluorouracil-based chemotherapy. The findings of Cas-
cinu et al. [11] are in agreement with a phase III study eval-
uating cetuximab in combination with gemcitabine com-
pared to gemcitabine alone in advanced pancreatic cancer. 
Seven hundred and thirty-five patients were randomly en-
rolled in this latter trial and 78% had metastatic disease. 
The median survival was 6 months in the gemcitabine arm 
and 6.5 months in the gemcitabine plus cetuximab arm, 
which fails to demonstrate a clinically significant advan-
tage of the addition of cetuximab to gemcitabine.
 In our study on 64 patients with metastatic pancreatic 
carcinoma, the addition of cetuximab to the combination 
of gemcitabine and oxaliplatin was well tolerated and ex-
hibited a high response rate (33%). The median time to 
progression-free survival was 3.9 months and overall sur-
vival was 7.1 months. Again, these findings do not seem 
to be superior to the results achieved in the previous stud-
ies of gemcitabine and oxaliplatin alone.
 What are the reasons for inactivity of cetuximab in 
pancreatic cancer and are there possibly predictive fac-
tors for response? No clinical studies evaluating efficacy 
of cetuximab molecular characterization including EGFR 
mutation have been reported so far.
 Seventy to 100% of ductal adenocarcinoma exhibit 
KRAS mutations and all mutations were located in codon 
12  [13, 14] . Differences were found between the type of 
mutations  [14, 15] . Immervoll et al.  [16]  screened a series 
of 43 formalin-fixed paraffin-embedded ductal adeno-
carcinoma of the pancreas. When DNA was extracted 
from whole tissue sections, KRAS codon 12 mutations 
were detected in 67% of the tumors. When cancerous 
ducts were isolated by laser-assisted microdissection, 91% 
were positive for KRAS mutations. In the present study 
we performed manual microdissections and obtained a 
tumor cell population of 70% in every case. However, in 
many cases mutation analyses were done on a limited 
number of cells. The mutation rate in the present study 
was on a lower limit compared to previous studies.
Time (days)
0
0 50 100 150 200 250 300 350 400 450 800
n = 14
n = 49
0.2
0.4
0.6
0.8
1.0
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No: n = 14, 10 events
Yes: n = 49, 37 events
(No)
(Yes)
log-rank test: p = 0.014, two-sided
500 550 600 650 700 750
8 6 4 2 1 1 1 0 0 0 0 0 0 0 0
46 39 27 23 18 11 8 8 8 5 3 2 2 1 1
 Fig. 3. Overall survival depending on rash. 
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 There was a trend that survival after diagnosis varied 
according to the KRAS mutation subtype. Patients with 
the Gly12Val mutation survived much longer (23.5 months) 
than patients with Gly12Asp mutations (9.5 months). Lee 
et al.  [17]  analyzed EGFR mutation by DNA sequencing of 
exon 18–21 in the tyrosine kinase domain in 65 pancreat-
ic cancer patients. Thirty-two (49%) of the 65 pancreatic 
adenocarcinomas examined harbored a point mutation 
in the KRAS gene. All KRAS mutations occurred at co-
don 12. The most frequently observed point mutation was 
Gly12Val. The presence of KRAS point mutations at codon 
12 adversely influenced median survival time (9.1 vs. 13.4 
months, KRAS mutation (+ vs. –), p = 0.03).
 To our knowledge, this is the first study assessing the 
relationship between KRAS mutations and response or 
survival in patients with metastatic pancreatic cancer 
treated with cetuximab plus chemotherapy. Overall sur-
vival was longer in wild-type patients compared to pa-
tients with KRAS mutations (263 vs. 162 days). The dif-
ference did not reach statistical significance probably due 
to small sample size.
 This is supported by recently reported preliminary data 
of the German AIO group on the role of KRAS mutation 
in erlotinib-treated patients with advanced pancreatic can-
cer  [18] . Within this prospective multicenter phase III trial 
281 patients were randomly assigned to first-line treatment 
with either capecitabine plus erlotinib or gemcitabine plus 
erlotinib. Tissue samples were available from 204 patients. 
123 tumors (70%) harbored a somatic KRAS mutation. Pa-
tients with KRAS wild type had a longer overall survival 
(wild type: 8.0 months vs. mutation: 6.6 months, HR 1.62, 
p = 0.011). On the other hand, in a molecular subset analy-
sis of patients from the NCIC CTG PA.3, the EGFR gene 
copy number and KRAS mutation status were not identi-
fied as markers predictive of a survival benefit from the 
combination of erlotinib with gemcitabine for the first-line 
treatment of advanced pancreatic cancer  [19] .
 Taken together, our results and others reported re-
cently in the literature provide evidence that KRAS mu-
tation in codon 12 is possibly associated with reduced 
survival compared to KRAS wild type. KRAS mutation 
could be a predictive marker in patients with advanced 
pancreatic cancer analogous to colorectal cancer patients 
treated with cetuximab. As our study was a single-arm 
trial with no cetuximab-free control arm, it could be 
possible that KRAS is just a prognostic marker and not 
predictive of cetuximab efficacy in pancreatic cancer. 
The primary limitation of the current study was as al-
ready mentioned above the low number of samples suit-
able for molecular analysis. Small sample size and poten-
tial selection bias make it difficult to draw firm conclu-
sions.
 Therefore, the role of EGFR targeting therapy in pa-
tients with KRAS wild-type pancreatic cancer warrants 
further investigation in larger trials to exclude an epiphe-
nomenon and confirm efficacy.
 A further analysis of our clinical phase II trial showed 
that the presence of rash was significantly correlated with 
overall survival, consistent with the results of Xiong et al. 
 [8] . A similar relationship between rash and clinical out-
come could be demonstrated in a large phase III study for 
patients with advanced pancreatic cancer treated with er-
lotinib  [6] . The reasons for the development of a rash are 
not fully understood. Possible explanations include dif-
ferences in drug exposure, integrity of the immune sys-
tem or EGFR polymorphisms  [20] .
 These findings support the vision of a more individu-
alized cancer treatment.
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